# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jean-Jacques Rousseau (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN003-SYN-TD
- Date: 1767-07-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Celestine Marchetti-Owusu, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Twelve-week review on aripiprazole; urethroplasty follow-up. **S**

## History of present illness

Mr. Rousseau returns twelve weeks after starting aripiprazole 5 mg and about sixteen weeks after urethroplasty. He sleeps about six and a half hours most nights. He still believes some former friends speak against him, but he now spends under an hour a day on these thoughts rather than most of the day, opens his letters, and has written most mornings for a month. He has had fourteen CBT sessions and plans two more. He has had no restlessness, nausea, stiffness, or new urges, and has taken the tablet every morning. The four-week weight check was missed while he was away walking in the hills; his weight was taken at the sick visit for back strain five weeks ago, which has fully resolved. He passes urine freely and gets up once at night at most. He has had no thoughts of suicide or of harming anyone. **S**

| Element | Detail |
|---|---|
| Sleep | About six and a half hours |
| Beliefs | Present, held less firmly; under an hour a day of preoccupation |
| Medication | Aripiprazole 5 mg daily; no side effects; no missed doses |
| Psychotherapy | Fourteen CBT sessions |
| Voiding | Free stream; up once at night at most |
| Back strain | Resolved within three weeks |
| Safety | No thoughts of suicide or of harming anyone |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight up slightly; no fatigue |
| Genitourinary | Negative | Strong stream; no spraying, burning, or blood |
| Musculoskeletal | Negative | Back pain resolved |
| Neurological | Negative | No restlessness, tremor, stiffness, or abnormal movements |
| Endocrine | Negative | No thirst or excessive urination |
| Psychiatric | Positive | Persecutory beliefs persist with less conviction and distress; no hallucinations; no new urges; no thoughts of suicide or of harming anyone |

6 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for pain, no more than 3000 mg a day **S**
- Aripiprazole 5 mg oral tablet, one tablet by mouth each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/78 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 64.4 kg; BMI 23.4 kg/m². All vital signs are synthetic.

PHQ-9: 4; IPSS symptom score: 5; IPSS quality-of-life score: 1; Maximum urine flow (uroflowmetry): 20.8 mL/s; Post-void residual (bladder scan): 30 mL; Creatinine: 0.99 mg/dL; eGFR: 91 mL/min/1.73 m²; Glucose (fasting): 94 mg/dL; Hemoglobin A1c: 5.5%; Total cholesterol: 201 mg/dL (high); HDL cholesterol: 47 mg/dL; LDL cholesterol: 126 mg/dL; Triglycerides: 138 mg/dL; Waist circumference: 93 cm. All results are synthetic.

## Change since baseline

- PHQ-9: 8 at baseline, 4 at this visit **S**
- IPSS symptom score: 24 at baseline, 5 at this visit **S**
- IPSS quality-of-life score: 5 at baseline, 1 at this visit **S**
- Maximum urine flow (uroflowmetry): 6.2 mL/s (low) at baseline, 20.8 mL/s at this visit **S**
- Post-void residual (bladder scan): 180 mL (high) at baseline, 30 mL at this visit **S**
- Creatinine: 1.02 mg/dL at baseline, 0.99 mg/dL at this visit **S**
- eGFR: 87 mL/min/1.73 m² at baseline, 91 mL/min/1.73 m² at this visit **S**
- Glucose (fasting): 93 mg/dL at baseline, 94 mg/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well and relaxed |
| Neurological | No tremor, rigidity, or involuntary movements; no akathisia |
| Genitourinary | Perineal scar healed; right inguinal hernia small and reducible, unchanged |
| Back | Full, painless movement |
| Mental status | Warm and courteous; mood "steadier than for years"; persecutory beliefs present but held with less conviction, and he can consider other explanations; no hallucinations; no suicidal or violent ideation |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Delusional disorder, persecutory type, on aripiprazole** (F22). Good partial response to combined CBT for psychosis and aripiprazole: preoccupation and distress much reduced, sleep restored, and writing resumed; the beliefs persist with less conviction, which is a realistic outcome. PHQ-9 4. No side effects. Twelve-week metabolic check: weight 64.4 kg (up 1.2 kg, 1.9 percent), waist 93 cm, blood pressure 124/78, fasting glucose 94 mg/dL, hemoglobin A1c 5.5 percent, LDL cholesterol 126 mg/dL; no clinically important change. **S**
   - Continue aripiprazole 5 mg each morning for at least a year, then review with him.
   - Complete the last two CBT sessions, with a written relapse-prevention plan.
   - Weight every three months; glucose, A1c, lipids, waist, and blood pressure yearly; AIMS at six months.
   - Safety plan reviewed and unchanged; the 988 Suicide & Crisis Lifeline confirmed.
2. **Bulbar urethral stricture after urethroplasty** (N35.812). Sustained result at about four months: maximum flow 20.8 mL/s, residual 30 mL, IPSS 5, quality of life 1; creatinine 0.99 mg/dL. **S**
   - Uroflowmetry and residual at six and twelve months with the urology team.
3. **Acute low back strain** (S39.012A). Resolved without imaging. **S**
   - Lift with bent knees and split wood in shorter spells.
4. **Right inguinal hernia** (K40.90). Unchanged and painless. **S**
   - Watchful waiting.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Suicide and violence risk review (C-SSRS Since Last Visit, PHQ-9 item 9, thoughts of harming others, plans to confront anyone, access to weapons) and the safety plan | Every visit | Completed today | No thoughts of suicide or of harming anyone; no plan to confront anyone; no weapons; PHQ-9 item 9 scored 0; safety plan reviewed |
| Survey | PHQ-9 for depressive symptoms | At least monthly | Completed today | 4, down from 8 at intake; monthly scores of 5 and 4 recorded at CBT sessions |
| Examination | Weight four weeks after starting aripiprazole | Weight at 4, 8, and 12 weeks | Deferred | Missed: the four-week weight was not taken because he was away and no visit was booked. The weight at seven weeks (64.0 kg, at the sick visit) and today's weight (64.4 kg, up 1.9 percent) show no clinically important gain, so no harm resulted. Corrective action: future early weight checks will be booked as nurse visits at the time a drug is started |
| Examination | Weight, BMI, waist, and blood pressure at twelve weeks | Weight at 12 weeks then quarterly; waist and blood pressure at 12 weeks then yearly | Completed today | 64.4 kg, BMI 23.4, waist 93 cm, 124/78 mmHg |
| Laboratory | Fasting glucose, hemoglobin A1c, and lipids at twelve weeks | Baseline, 12 weeks, then yearly | Completed today | Glucose 94 mg/dL, A1c 5.5 percent, total cholesterol 201, HDL 47, LDL 126, triglycerides 138 mg/dL |
| Examination | Akathisia check | Each visit on an antipsychotic | Completed today | None |
| Examination | AIMS | Baseline and every 6 months | Due | Next at six months on aripiprazole |
| Medication safety | Adherence and adverse-effect review | Every visit | Completed today | No missed doses; no nausea, restlessness, or impulse-control symptoms |
| Referral | Cognitive behavioral therapy for psychosis | About 16 sessions | Completed today | Fourteen sessions; two more planned with a relapse-prevention plan |
| Survey | IPSS and quality-of-life score | At each surveillance visit | Completed today | IPSS 5; quality of life 1 |
| Imaging | Uroflowmetry and post-void residual | About 3, 6, and 12 months after urethroplasty | Completed today | Maximum flow 20.8 mL/s; residual 30 mL |
| Imaging | Urethroscopy or urethrogram | Only with symptoms or a fall in flow | Not indicated | No symptoms and a normal flow |
| Laboratory | Creatinine and eGFR | Yearly after relief of obstruction, or with symptoms | Completed today | 0.99 mg/dL; eGFR 91 |
| Examination | Inguinal hernia check | At each review while under watchful waiting | Completed today | Unchanged |

## Goal progress

- Sleep at least six hours most nights. Outcome by 1767-07-14: About six and a half hours most nights by twelve weeks on aripiprazole. **S**
- Less distress and preoccupation from the beliefs, so that he can write each morning and walk without fear. Outcome by 1767-07-14: Preoccupation down from most of the day to under an hour; writing most mornings; the beliefs persist with less conviction. **S**
- Stay in care: keep visits and psychotherapy sessions, with no sudden break in treatment. In progress; target 1767-12-15. **S**
- Pass urine with a free stream without self-dilation: maximum flow above 15 mL/s and post-void residual below 100 mL within three months of surgery. Outcome by 1767-07-14: Maximum flow 20.8 mL/s and residual 30 mL four months after urethroplasty; no sounds used since January. **S**
- No harm to himself or anyone else; safety plan kept current. In progress; target 1767-12-15. **S**

## Guideline basis

- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition. Am J Psychiatry 2020;177(9):868-872 (2020), American Psychiatric Association
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (PHQ-9, suicide-risk review, and second-generation antipsychotic monitoring) (2026), Aether Forge
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- Urethral Stricture Disease: AUA Guideline Amendment (2023). Wessells H, et al. J Urol 2023;210(1):64-71. PMID 37096574 (2023), American Urological Association
- International guidelines for groin hernia management. HerniaSurge Group. Hernia 2018;22(1):1-165 (2018), HerniaSurge Group (European Hernia Society and partner societies)

## Follow-up

- Last two CBT sessions; urology flow test at six months; weight in three months; preventive visit in the autumn. **S**
- Next scheduled visit 1767-09-22: adult preventive visit. **S**
